CompanyGraph
Inner Mongolia Furui Medical Science Co., Ltd.
300049 · SZSE · China
fu-rui.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.61B, above the global median of $1.15B
- FinancialsAltman Z-Score 8.27: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.03%
Annual Rate
CNY 0.01Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 6, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.84BCNY1.61B · vs all stocks (USD)
Trailing P/E
74.42xvs Biotechnology peers
Revenue (TTM)
1.63BCNY241.36M · vs all stocks (USD)
Profit Margin
9.68%vs Biotechnology peers
Beta
-0.2750xvs all stocks
52-Week Change
-39.62%vs all stocks
Market Capitalization
10.84BCNY1.61B · vs all stocks (USD)
Enterprise Value
11.71BCNY1.74B · vs all stocks (USD)
Trailing P/E
74.42xvs Biotechnology peers
Forward P/E
32.29xvs Biotechnology peers
Price to Sales (TTM)
7.13xvs Biotechnology peers
Price to Book (MRQ)
5.87xvs Biotechnology peers
Enterprise to Revenue
7.20xvs Biotechnology peers
Enterprise to EBITDA
24.27xvs Biotechnology peers
Gross Margin
74.89%vs Biotechnology peers
Profit Margin
9.68%vs Biotechnology peers
Operating Margin
19.46%vs Biotechnology peers
Return on Assets (TTM)
7.73%vs Biotechnology peers
Return on Equity (TTM)
11.52%vs Biotechnology peers
Revenue (TTM)
1.63BCNY241.36M · vs all stocks (USD)
Revenue per Share (TTM)
6.09CNYUpdated Aug 19, 2026Quarterly Revenue Growth
9.00%vs Biotechnology peers
Gross Profit (TTM)
1.21BCNY179.88M · vs all stocks (USD)
EBITDA (TTM)
325.65MCNY48.36M · vs all stocks (USD)
Net Income (TTM)
157.25MCNY23.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
11.00%vs Biotechnology peers
Operating Cash Flow (TTM)
367.88MCNY54.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
328.72MCNY48.82M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0150CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.03%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
493.26MCNYFY2025 · Dec 31, 2025Revenue
1.60BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
399.36MCNYFY2025 · Dec 31, 2025Gross Profit
1.20BCNYFY2025 · Dec 31, 2025Operating Income
399.40MCNY59.32M · vs all stocks (USD)
Pre-tax Income
350.56MCNYFY2025 · Dec 31, 2025Income Tax Expense
92.14MCNYFY2025 · Dec 31, 2025Net Income
258.42MCNYFY2025 · Dec 31, 2025EBIT
353.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
461.30MCNYFY2025 · Dec 31, 2025Research & Development
111.20MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
171.86MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
19.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.22MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
265.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
265.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
258.42MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-104.33MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
165.48MCNYFY2025 · Dec 31, 2025Free Cash Flow
-19.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
640.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
258.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
38.78MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-120.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.09MCNYFY2025 · Dec 31, 2025Capital Expenditures
-184.56MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.37BCNYFY2025 · Dec 31, 2025Sale of Investments
1.37BCNYFY2025 · Dec 31, 2025Other Investing Activity
-28.70MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-213.03MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
12.40MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-59.70MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-49.58MCNYFY2025 · Dec 31, 2025Shares Outstanding
264.98MSharesUpdated Aug 19, 2026Float Shares
203.80MSharesUpdated Aug 19, 2026% Held by Insiders
23.90%vs all stocks
% Held by Institutions
12.46%vs all stocks
Total Cash (MRQ)
749.08MCNY111.25M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.83CNYUpdated Aug 19, 2026Total Debt (MRQ)
79.96MCNY11.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0322xvs Biotechnology peers
Current Ratio (MRQ)
3.44xvs Biotechnology peers
Book Value per Share (MRQ)
7.48CNYUpdated Aug 19, 2026Total Assets
3.44BCNY510.75M · vs all stocks (USD)
Total Current Assets
1.54BCNYFY2025 · Dec 31, 2025Total Liabilities
967.33MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.89BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
485.08MCNYFY2025 · Dec 31, 2025Total Current Liabilities
482.25MCNYFY2025 · Dec 31, 2025Cash
640.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
9.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
649.74MCNYFY2025 · Dec 31, 2025Other Short-term Investments
83.62MCNYFY2025 · Dec 31, 2025Accounts Receivable
445.27MCNYFY2025 · Dec 31, 2025Inventory
148.97MCNYFY2025 · Dec 31, 2025Accounts Payable
128.75MCNYFY2025 · Dec 31, 2025Short-term Debt
106.55MCNYFY2025 · Dec 31, 2025Other Current Liabilities
12.82MCNYFY2025 · Dec 31, 2025Long-term Debt
69.43MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.18MCNYFY2025 · Dec 31, 2025Common Stock (Book)
264.98MCNYFY2025 · Dec 31, 2025Retained Earnings
915.91MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.47BCNY367.08M · vs all stocks (USD)
Treasury Stock
34.78MCNYFY2025 · Dec 31, 202552-Week Low
36.50CNYUpdated Aug 19, 202652-Week High
90.68CNYUpdated Aug 19, 202652-Week Change
-39.62%vs all stocks
Beta
-0.2750xvs all stocks
50-Day MA
42.76CNYUpdated Aug 19, 2026200-Day MA
58.05CNYUpdated Aug 19, 2026Avg 10-Day Volume
10.96MSharesUpdated Aug 19, 2026Avg 30-Day Volume
10.08MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.5900CNYUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 8.27: safe zoneNotable
Altman Z-Score: 8.27
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.61B, above the global median of $1.15BNotable
Market cap (USD): 1,609,878,801.603Global Median: 1,146,734,693.424
Levered free cash flow is $48.82M, above the global median of $16.24MNotable
Levered free cash flow (USD): 48,821,798.569Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MoonLake Immunotherapeutics
Tier 1ProductionApproval-Gated PipelineRuleRisk
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Porton Pharma Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen Woer Heat-Shrinkable Material Co., Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Sprouts Farmers Market Inc.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Huaming Power Equipment Co., Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated